GO
Loading...

Health Care

More

  • 'Fine' not dandy, says California Obamacare boss Tuesday, 13 Jan 2015 | 4:13 PM ET
    Homepage of Covered California

    California's Obamacare exchange has signed up 217,000 new customers, but plans to get more by warning uninsured people about increasing fines.

  • Biopharma's challenges in 2015  Wednesday, 14 Jan 2015 | 9:30 AM ET

    Biopharma executives at the J.P. Morgan Healthcare Conference talk about this year's biggest challenges.

  • Navellier’s crunching finds growth for cheap Wednesday, 14 Jan 2015 | 6:00 AM ET
    Actavis Group headquarters is shown in Hafnarfjordur, Iceland, April 20, 2006.

    Louis Navellier says crunching the numbers for stocks that move independent of the market point him to two drug companies and a Chinese retailer.

  • Ariad CEO: Expanding Iclusig  Tuesday, 13 Jan 2015 | 1:47 PM ET

    Ariad CEO Harvey Berger, tells CNBC's Meg Tirrell commercially the company had a good year and provides insight into its new cancer drug, Iclusig.

  • CEO: 2015 exciting for Vertex  Tuesday, 13 Jan 2015 | 3:10 PM ET

    Vertex CEO Dr. Jeffrey Leiden tells CNBC's Meg Tirrell about the company's new drug trials and focus areas in 2015.

  • Martha Stewart ordeal changed me: Sam Waksal Tuesday, 13 Jan 2015 | 11:24 AM ET
    Sam Waksal of Kadmon Pharmaceuticals

    "Any event in life changes one. That was an event that probably changed me in many ways. I think I am a better person," biotech company founder Sam Waksal.

  • Orexigen CEO: Excited about obesity drug progress  Tuesday, 13 Jan 2015 | 2:22 PM ET

    Mike Narachi, Orexigen CEO, speaks with CNBC's Meg Tirrell about its obesity drug and program.

  • Juno's promising CAR-T immunotherapy  Tuesday, 13 Jan 2015 | 5:15 PM ET

    Hans Bishop, Juno Therapeutics co-founder and CEO, discusses promising data for new cancer immunotherapy approaches.

  • Health insurance paperwork wastes $375 billion Tuesday, 13 Jan 2015 | 11:54 AM ET

    A study says trillions of dollars could be saved in health-care billing and insurance administrative costs over the course of years.

  • Cigna's expansion strategy  Tuesday, 13 Jan 2015 | 10:17 AM ET

    David Cordani, Cigna president & CEO, weighs in on rival Aetna's wage plan and explains Cigna's growth strategy.

  • Chimerix tackles Ebola outbreak  Tuesday, 13 Jan 2015 | 11:46 AM ET

    Michelle Berrey, Chimerix CEO, discusses the testing of its Ebola drug Brincidofovir in a clinical setting in West Africa, with CNBC's Meg Tirrell.

  • Valeant CEO: Allegations about our business not true  Tuesday, 13 Jan 2015 | 12:46 PM ET

    Valeant CEO Mike Pearson tells CNBC's Meg Tirrell the company is on a mission to prove allegations against the business model are not true. Pearson says Valeant is unlikely to work with Bill Ackman.

  • The U.K.’s National Health Service, for decades a global case-study in universal healthcare, seems to be facing its biggest ever crisis of confidence.

  • Sass bets on airline, hedge fund stock Monday, 12 Jan 2015 | 12:00 AM ET
    A ground crewmember prepares to push back an American Airlines Boeing 737-823 jet at a terminal at  Miami International Airport.

    Martin D. Sass' stock picks are trades in three popular sectors: airlines, pharmaceuticals and asset management.

  • I am a better person: Sam Waksal  Tuesday, 13 Jan 2015 | 8:36 AM ET

    Sam Waksal, former Imclone Systems CEO, reveals how the ImClone scandal has impacted his life.

  • J&J CEO: Too early to fully assess Obamacare  Monday, 12 Jan 2015 | 5:43 PM ET

    Alex Gorsky, Johnson & Johnson chairman and CEO, discusses how the ACA and the recovery in the economy is impacting business.

  • Shire CEO: $5.2 billion NPS deal will pay off  Monday, 12 Jan 2015 | 5:16 PM ET

    Flemming Ornskov, Shire CEO, tells CNBC's Meg TIrrell it is the right time for the proposed acquisition of NPS Pharmaceuticals.

  • Merck CEO: Deals create value  Monday, 12 Jan 2015 | 4:27 PM ET

    Merck CEO Ken Frazier plans to focus on its specialized area strategy in 2015, with CNCB's Meg Tirrell.

  • Biogen Idec beefs up pain pipeline  Monday, 12 Jan 2015 | 3:16 PM ET

    Dr. George Scangos, Biogen Idec CEO, discusses new therapies in multiple sclerosis, Alzheimer's disease and pain.

  • Targeting cancer's metabolism  Monday, 12 Jan 2015 | 2:46 PM ET

    Dr. David Schenkein, Agios CEO, explains a cancer's metabolism, and the company's priorities for 2015.

Contact Health Care

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    To learn more about how we use your information,
    please read our Privacy Policy.
    › Learn More

 

  • Dan Mangan is a reporter covering health care for CNBC.com.

  • Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals.

  • Bertha Coombs is a general assignment reporter for CNBC, covering financial markets and business news stories.